menu
    • menu
    [{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical Countermeasure to Nerve Agents","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CMC Pharmaceuticals \/ U.S. Defense Department","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ U.S. Defense Department"}]

    Find Clinical Drug Pipeline Developments & Deals for alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester

    Menu

    alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CMC Pharmaceuticals

                            U.S.A arrow
                            World Dairy Expo 2024
                            Not Confirmed

                            CMC Pharmaceuticals

                            U.S.A arrow
                            World Dairy Expo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate,Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : U.S. Defense Department

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical...

                            Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2022

                            Lead Product(s) : Atropine Sulfate,Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : U.S. Defense Department

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4